Pharmaron and CR MedIcon Sign an Investment and Strategic Partnership Agreement

Beijing, China, May 18, 2018 – Pharmaron, a global leading life science service company headquartered in Beijing, announced today that it has entered into a definitive investment and strategic partnership agreements with CR Medicon Holding Inc. and its wholly owned subsidiary, Nanjing CR MedIcon Pharmaceutical Technology Co., Ltd. (“CR Medicon”), a clinical CRO based in Nanjing. This investment and strategic partnership will accelerate the establishment of a world-class clinical CRO platform.

With the strategic investment in CR Medicon, Pharmaron and CR MedIcon will become a strategic partner in the area of clinical development services in China. Both parties will dedicate their resources, technology and marketing capability to establish a world-class clinical CRO platform with the goal to accelerate the clinical development process for our partners. 

“As a fast growing clinical CRO in China, CR MedIcon strives to provide high quality clinical services to our partners. We are excited to have Pharmaron, a respected global player in the life science services industry, as our strategic partner in the clinical development service area in China. We are confident this strategic partnership will better serve the pharmaceutical R&D community,” said Dr. Henry Wu, Founder, CR MedIcon.

“The strategic investment and partnership with CR MedIcon will strengthen Pharmaron’s clinical development service capabilities, which is an important component of our growth strategy. Together with the successful 2017 acquisition of the majority stake in SNBL Clinical Pharmacology Center in the USA (now Pharmaron CPC), the new partnership has uniquely positioned Pharmaron to provide comprehensive and value-added clinical development services to our partners,” said Mr. Larry Lou, President and COO, Pharmaron.

By combining both parties’ capabilities in clinical development services area, this strategic partnership expands Pharmaron’s fully integrated drug discovery and development service platform.  This arrangement further demonstrates the company’s commitment to become a global leader in the life science service industry. Pharmaron continues to uphold our original aspiration to support our partners’ success in discovery, development and commercialization of innovative medicines.

About CR MedIcon

CR MedIcon was established in 2017. As a clinical CRO, CR MedIcon’s major business includes regulatory affairs, medical affairs, clinical operation, clinical data management and biostatistics and bioanalysis of clinical samples to support the needs from clinical trial phases I-III/IV and BE. The company founder, Dr. Henry Wu, has extensive experience in the clinical research field in the USA and China. He obtained his BSc from Qinghua University, China, and his PhD in Biostatistics from Rutgers University, USA. With over 120 employees, CR MedIcon provides clinical research services to more than 40 clients. 

About Pharmaron 

Pharmaron is a private, premier R&D service provider for the life science industry. Founded in 2004, Pharmaron has invested in its people and facilities, and established a broad spectrum of drug R&D service capabilities, ranging from analytical chemistry, synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabelled metabolism, 14C-microtracer/AMS platform, chemical & pharmaceutical development to clinical development, including integrated services covering the entire drug discovery and development process with CRMO solutions. With over 6,600 employees and operations in China, the U.S. and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China.